BSG and ovarian cancer: The inhibition of CD147, P-gp, and p-Akt by STAT3 decoy oligodeoxynucleotide (ODN) technology inhibits ovarian cancer cell invasiveness and enhances the paclitaxel sensitivity of SKOV3 and OVCAR3 ovarian cancer cells [149].